Quarterly report pursuant to Section 13 or 15(d)

Statement of Cash Flows

v3.5.0.2
Statement of Cash Flows - USD ($)
2 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2016
Cash Flows from Operating Activities:    
Net loss $ (224,315) $ (2,503,047)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 0 1,629
Stock-based compensation 0 208,939
Shares issued for licenses used for research and development 2,061 0
Changes in operating assets and liabilities:    
Prepaid expenses (23,000) (244,869)
Accounts payable and accrued expenses 63,010 (146,799)
Accounts payable and accrued expenses - related parties 19,584 87,500
Net Cash Used in Operating Activities (162,660) (2,596,647)
Cash Flows from Investing Activities:    
Cash paid for purchase of fixed assets 0 (10,155)
Cash paid for acquisition of Moleculin, LLC, net with cash acquired 0 (99,638)
Net Cash Used in Investing Activities 0 (109,793)
Cash Flows from Financing Activities:    
Proceeds from notes payable 250,000 165,000
Payments on notes payable 0 (469,939)
Proceeds from sale of common stock, net of direct offering costs 0 9,167,071
Net Cash Provided by Financing Activities 250,000 8,862,132
Net change in cash and cash equivalents 87,340 6,155,692
Cash and cash equivalents, at beginning of period 0 28,091
Cash and cash equivalents, at end of period 87,340 6,183,783
Supplemental disclosures of cash flow information:    
Cash paid for interest 0 47,950
Cash paid for income taxes 0 0
Supplemental disclosure of non-cash investing and financing activities:    
Common stock issued to acquire Moleculin, LLC 0 9,773,586
Common stock issued for conversion of debt 0 341,785
Shares subscribed $ 4,600 $ 0